Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis, page-60

Fast approaching another SNT 5505 Phase II Interim MARCH Data Announcement

On the 14th of November the Trial Participant numbers and stage they were at was

13 Patients had reached 12 weeks of Treatment
8 Patients had reached 24 weeks of Treatment
5 Patients had reached 38 weeks of Treatment

That was now 15.4 weeks ago so the new numbers are

13 Patients had reached 27.4 weeks of Treatment
8 Patients had reached 39.4 weeks of Treatment
5 Patients have now completed the 52 weeks of Trial Treatment and with no ASX Announcement to state otherwise "No Serious Adverse Effects Monitored"

One would think SNT or their PR company would be preparing the market for the next set of what looks again loke Positive Data reinforcing the previous Positive Interim update that saw the SP shift up 28% on release.. that would see us move into double digits today.

The only thing holding SNT back IMHO is poor market messaging ,, the ASX Biotech community should all be aware of SNT and the next set of results on the near term horizon ....

Come on Syntara wheres the market messaging?? NZT



Come on SNT prime the market for the next round of Phase II Data...